Randomized, Controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali.
Phase of Trial: Phase I
Latest Information Update: 29 Feb 2016
At a glance
- Drugs AS02 (Primary) ; Malaria vaccine (Primary) ; Rabies vaccine
- Indications Falciparum malaria; Rabies
- Focus Adverse reactions; Pharmacodynamics
- 14 Oct 2011 Additional lead trial centers identified as reported by ClinicalTrials.gov.
- 04 Feb 2009 Actual patient numbers (100) added as reported by ClinicalTrials.gov.
- 04 Sep 2008 Actual start date changed from Nov 2006 to Oct 2006 as reported by Clinicaltrials.gov